Kaleb Michaud
Overview
Explore the profile of Kaleb Michaud including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
248
Citations
7121
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopez-Olivo M, Kachira J, Madramootoo S, Michaud K, Schumacher R, Cinciripini P, et al.
Arthritis Care Res (Hoboken)
. 2025 Jan;
PMID: 39828986
Objective: In this study, we explored physicians' level of experience with patients with rheumatoid arthritis (RA) who used tobacco, their views on the effects of tobacco use on the efficacy...
2.
Song W, Michaud K, Lonowski S, Kaufmann M, Pearson R, Del Rosso J, et al.
J Psoriasis Psoriatic Arthritis
. 2024 Nov;
:24755303241303089.
PMID: 39583218
Background: Real-world evidence describing the natural history of all manifestations and severities of psoriasis is needed, as existing studies often recruit from a restricted patient population, and treatment failure and...
3.
Katz P, Pedro S, Park J, Choi J, Michaud K
ACR Open Rheumatol
. 2024 Oct;
6(12):918-926.
PMID: 39381836
Objective: Glucocorticoids (GCs) can be beneficial from both clinical and patient perspectives, but side effects are well documented. We examined patterns of GC use over 15 years (2006-2021) and occurrence...
4.
Liew J, Pedro S, Michaud K, Ogdie A
J Rheumatol
. 2024 Aug;
51(10):1009-1014.
PMID: 39147415
Objective: Opioid use among individuals with spondyloarthritis is common; however, data on whether these individuals have higher utilization of the healthcare system are lacking. We examined the association between opioid...
5.
Simon T, Suissa S, Skovron M, Frisell T, Askling J, Michaud K, et al.
Semin Arthritis Rheum
. 2023 Dec;
64:152313.
PMID: 38044241
Objective: To evaluate risk of infections requiring hospitalization and opportunistic infections, including tuberculosis, in patients with rheumatoid arthritis (RA) treated with abatacept versus conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs)...
6.
Michaud K, Pedro S, Tousset E, Schumacher R, Agarwal E, Vrijens B
ACR Open Rheumatol
. 2023 Dec;
6(2):72-80.
PMID: 38041515
Objective: To assess tofacitinib and self-injectable tumor necrosis factor inhibitor (TNFi) adherence using the Medication Event Monitoring System (MEMS) and characterize association with adherence in patients with rheumatoid arthritis (RA)....
7.
Simon T, Dong L, Suissa S, Michaud K, Pedro S, Hochberg M, et al.
Ann Rheum Dis
. 2023 Nov;
83(2):177-183.
PMID: 37932010
Objectives: This study aims to evaluate non-melanoma skin cancer (NMSC) risk associated with abatacept treatment for rheumatoid arthritis (RA). Methods: This evaluation included 16 abatacept RA clinical trials and 6...
8.
Sparks J, Harrold L, Simon T, Wittstock K, Kelly S, Lozenski K, et al.
Semin Arthritis Rheum
. 2023 Aug;
62:152249.
PMID: 37573754
Objective: To assess real-world comparative effectiveness studies of biologic (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) in adults with rheumatoid arthritis (RA) through a systematic review. Methods: We...
9.
Katz P, Pedro S, Michaud K
Arthritis Care Res (Hoboken)
. 2023 Jul;
75(12):2543-2544.
PMID: 37518816
No abstract available.
10.
Simon T, Suissa S, Boers M, Hochberg M, Skovron M, Askling J, et al.
Semin Arthritis Rheum
. 2023 Jul;
64:152240.
PMID: 37500379
Objective: To evaluate the risk of malignancy (overall, breast, lung, and lymphoma) in patients with rheumatoid arthritis treated with abatacept, conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs), and other biologic/targeted...